Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3575-80-2
Molecular formula
C16H22FNO
Molecular weight
263.35 g/mol
Drug class
Butyrophenone antipsychoticdopamine and serotonin receptor antagonist
Mechanism of action
Has weak dopamine D2 receptor affinity relative to many conventional neuroleptics and modulates central dopaminergic, serotonergic and adrenergic signalling. Its atypical pharmacological profile is associated with antipsychotic and sedative effects with comparatively limited extrapyramidal effects in some studies.
Indications / reported uses
Treatment of psychotic disorders and selected behavioural disturbances in countries where melperone remains authorised; exact indication depends on local product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Melperone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Melperone Permitted Daily Exposure (PDE) report (the Melperone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Melperone Occupational Exposure Limit (OEL) report (the Melperone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.